Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05687435

Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Diarrhea-Predominant Irritable Bowel Syndrome Clinical Trial

Official title:
Changyanning Tablet for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D): A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial

Clinical Trial Summary

The goal of this clinical trial is to test the efficacy and safety of the Chinese patent medicine Changyanning Tablet in the patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D). The main questions it aims to answer are: 1. Can Changyanning Tablet improve diarrhea and abdominal pain in IBS-D patients? 2. Is Changchangning Tablet safe for the treatment of IBS-D?

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05687435
Study type Interventional
Source Beijing University of Chinese Medicine
Contact Mei Han, Dr
Phone +8613401131731
Email hanmeizoujin@163.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date January 30, 2023
Completion date April 30, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04095988 - Allogeneic Microbiota-reconstitution (AMR) in Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) N/A
Completed NCT01736423 - A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome Phase 3
Completed NCT02612649 - Special Drug Use Surveillance of Irribow in Female Patients
Completed NCT01414244 - Glutamine for the Treatment of Patients With Irritable Bowel Syndrome Phase 2
Completed NCT03977155 - Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT02163213 - Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D N/A
Terminated NCT01358708 - Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg Phase 3
Not yet recruiting NCT06346847 - Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS N/A
Completed NCT01870895 - A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS) Phase 3
Recruiting NCT05593367 - Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
Completed NCT02538692 - Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Phase 2/Phase 3
Completed NCT03099785 - Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D Phase 2
Recruiting NCT05369884 - Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D Early Phase 1
Completed NCT01350570 - Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial Phase 2/Phase 3